Sevoflurane, Isoflurane and Desflurane Market Research and Forecasts, to 2022

1
Your Catalyst to a Lucrative Business
Sevoflurane, Isoflurane and Desflurane Market
Share, Size, Analysis, Growth, Trends and
Forecasts to 2022 Hexa Research
Sevoflurane, Isoflurane and Desflurane
Market Analysis Till 2022
Overview
The Sevoflurane, Isoflurane and Desflurane Market
is expected to reach USD 1.5 billion by 2022
in comparison to USD 1.2 billion in 2014. These
three chemicals are inhalation agents and have
been used by anesthesiologists, nurse
anesthetists, and anesthesiology assistants on a
consistent basis. They are very strong and cost
less, with minimum damage to the ozone layer.
Market Drivers
One of the primary factors, triggering expansion
in the sevoflurane, isoflurane and desflurane
market includes cardiovascular and respiratory
diseases affecting the geriatric population.
Rising cancer, orthopedic, spinal and
gastro-intestinal cases have also furthered the
market. Cataract surgery is a major contributor
to the global market and will need a higher
production of these chemicals. Growing accidents
and emergency cases also add income to the
inhalation anesthesia market. Universal insurance
coverage as well as constant improvements in
medical infrastructure also ensure the
development of the sevoflurane, isoflurane and
desflurane market. These agents are administered
to patients prior surgery, making the induction
of general anesthesia much simpler.
A major factor hindering the market is the
quantity of CO released in the environment,
leading to global
2
warming. Actually, only about 5 percent of the
gases are consumed by patients. The rest are
released into the atmosphere and make it
unhealthy. The most practical solution for this
problem is the anesthetic recycling of products
used during the administration of general
anesthesia.
Browse Details of Report _at_ http//www.hexaresearch
.com/research-report/sevoflurane-isoflurane- desfl
urane-industry/
Follow Us
2
Your Catalyst to a Lucrative Business
Products Overview Sevoflurane
Sevoflurane is one of the most commonly used
volatile anesthetic agents. It is administered to
babies and children. Sevoflurane is ideal for
patients with asthma or sensitive air passages.
But its side-effects include delirium and
agitation. It can be given quickly without the
use of intravenous instruments.
Sevoflurane would capture over 70 of the
worldwide sevoflurane, isoflurane and desflurane
market by 2022. The agent is expected to exceed
USD 1 billion by the same year. Its widely
utilized for being low-priced and possessing
therapeutic benefits.
Isoflurane
Isoflurane is a halogen ether utilized frequently
by veterinarians. It is administered
intravenously, relaxes the muscles and reduces
pain. Isoflurane has also been used for inducing
sleepiness for long durations during surgery. It
is expected to register a CAGR of about 10 by
2022.
Desflurane
Desflurane is a halogen ether used in general
anesthesia. Its effectiveness is one-fifth of
isoflurane. Desflurane cannot be administered
orally and requires an electrically heated
dispenser to distribute the vapor. It is mostly
administered to bariatric patients and in cases
of surgeries lasting for short durations.
Regional Overview
The United States has a large geriatric
population. This has led the region of North
America to occupy the biggest share in the
worldwide inhalation anesthesia market in 2014.
Surgical ambulatory and inpatient procedures are
the driving factors of North America.
Asia Pacific will experience the fastest growth
by 2022. This is owing to the rise of chronic
diseases and need for better health
infrastructure in the region. Medical tourism
combined with insurance coverage will play a huge
role in sustaining the growth of the sevoflurane,
isoflurane and desflurane market.
Key Players
The market is currently dominated by AbbVie and
Baxter International. However, it can expect
strong competition from manufacturers like Lunan
Pharmaceutical Group and Piramal Enterprises.
Piramal Enterprises currently has isoflurane and
sevoflurane production underway. It will
manufacture generic desflurane by 2016. AbbVie
has sevoflurane and isoflurane under production.
Baxter International is the only one that
manufactures all the three products.
Anesthesia has some unhealthy effects. The
recycling companies of Deltasorb Technologies and
Anesthetic Gas Reclamation reprocess anesthesia
containers and gases from hospital vents. Rising
investments by the aforementioned players would
also accelerate the sales of the sevoflurane,
isoflurane and desflurane market.
Browse Related Category Market Reports _at_
https//www.hexaresearch.com/research- category/ph
armaceuticals-industry
Follow Us
3
Your Catalyst to a Lucrative Business
Table of Content of Sevoflurane, Isoflurane and
Desflurane Market
Executive Summary Digital Transformation
industry critical success factors Industry Outlook
Industry Dynamics
Digital Transformation Market drivers Digital
Transformation Market restraints Digital
Transformation Key Market Opportunities Digital
Transformation Porters Analysis Digital
Transformation - PESTEL Analysis Digital
Transformation - Company Market Share
Analysis Digital Transformation Application
Outlook Digital Transformation Regional
Outlook Digital Transformation Company profiles
Research Methodology Research scope
assumptions List of data sources
Follow Us
4
Your Catalyst to a Lucrative Business
About Us
Hexa Research is a market research and consulting
organization, offering industry reports, custom
research and consulting services to a host of key
industries across the globe. We offer
comprehensive business intelligence in the form
of industry reports which help our clients obtain
clarity about their business environment and
enable them to undertake strategic growth
initiatives.
Contact Us
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018 United States
Phone [phone] Email sales_at_hexaresearch.c
om Website - https//www.hexaresearch.com/
Follow Us